PEDIATRICS Vol. 65 No. 3 March 1980, pp. 550-556
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Collen, R. J.
Right arrow Articles by Lippe, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Collen, R. J.
Right arrow Articles by Lippe, B. M.

Remission Rates of Children and Adolescents with Thyrotoxicosis Treated with Antithyroid Drugs

Roberta J. Collen MD1, Elliot M. Landaw MD1, Solomon A. Kaplan MD1, and Barbara M. Lippe MD1

1 Departments of Pediatrics and Biomathematics, Center for Health Sciences, University of California at Los Angeles School of Medicine, Los Angeles

The clinical course of 65 children with hyperthyrodism in whom antithyroid medication was initiated has been reviewed retrospectively. Fifty-five patients received only this projected medical therapy with propylthiouracil or methimazole. Sustained remission in excess of one year following cessation of drugs occurred in 31 patients (56%). All but two achieved that remission within 4.5 years. Of the 31 patients, 24 have been followed-up for more than two years off medication with only one relapse. Twenty-four patients are still under medical therapy, 14 for longer than 4.5 years. By methods of life-table analysis, the data on all 65 patients gave an estimate of 25% remitting within the first two years and a median remission time of 4 to 4.5 years. These results suggest a continuing remission rate of 25% every two years for up to six years of follow-up. Analysis of presenting variables (assessment of age at onset of disease, sex, family history, initial laboratory data, gland size, and degree of exophthalmos) that might have distinguished which patients were likely to undergo remission was attempted. There were no clearly significant differences with any of these variables although several suggestive differences emerged. These included a tendency toward earlier remission in patients older than 13 years, in boys of any age, and in patients of any age or sex in whom initial triiodothyronine (T3 RIA) < was 645 ng/100 ml. An approach to long-term medical management is proposed.

Submitted on February 5, 1979
Accepted on July 17, 1979




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
F. Kaguelidou, C. Alberti, M. Castanet, M.-A. Guitteny, P. Czernichow, J. Leger, and for the French Childhood Graves' Disease Study Gro
Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug Treatment
J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3817 - 3826.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Glaser and D. Styne
Childhood Graves' Disease--Remission Rate and Risk Factors--Authors' Responsef
J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1398a - 1399.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. S. Glaser and D. M. Styne
Predictors of Early Remission of Hyperthyroidism in Children
J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1719 - 1726.
[Abstract] [Full Text] [PDF]